Physician profile
Scott Zander
NPI 1568466241
$1,419.98
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,054 · 2020: $280 · 2021: $85.66.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $304.53 | 2019 | |
| Ironshore Pharmaceuticals INC. | $291.89 | 2019-2021 | |
| Tris Pharma INC | $281.79 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $116.27 | 2019 | |
| Neos Therapeutics, LP | $92.85 | 2019-2021 | |
| Adlon Therapeutics L.P. | $90.36 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.97 | 2019 | |
| Genentech USA, INC. | $51.17 | 2019-2020 | |
| Glaxosmithkline, LLC. | $39.92 | 2020 | |
| Vertical Pharmaceuticals, LLC | $38.54 | 2019-2020 | |
| Sobi, INC | $19.59 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $14.55 | 2019 | |
| Phadia US INC. | $11.55 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Zander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.